Evaluation of Pharmacogenetic Testing In a Mental Health Population and Economic Outcomes

Completed

Conditions studied: Major Depressive Disorder 1

In brief

This is a non-randomized, single-case design of pharmacogenetic implementation in a mental health patient population of subjects taking antipsychotics and/or antidepressants.

Key facts

Study ID

NCT02474680

Run by

Avera McKennan Hospital & University Health Center

People needed

84

Starts

2015-11-01

Expected to finish

2017-01-01

Last updated by the study team

2017-05-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must be taking either an anti-depressant or an anti-psychotic medication
• Must provide informed consent
• Must have Avera Health Plans insurance coverage
• Must have three months of participation in the Avera Care Coordination Program

You may not qualify if…

• Must not be pregnant or breastfeeding
• Must not have an active and/or unstable diagnosis of substance abuse
• Must not have a primary diagnosis of dementia, bulimia, or anorexia nervosa disorder
• Must not have had a previous pharmacogenetic evaluation

Where it is running

• Avera Institute for Human Genetics — Sioux Falls, South Dakota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.